Log in
NYSE:AMRX

Amneal Pharmaceuticals Stock Forecast, Price & News

$4.48
+0.20 (+4.67 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$4.27
Now: $4.48
$4.48
50-Day Range
$3.54
MA: $4.13
$5.27
52-Week Range
$2.40
Now: $4.48
$5.79
Volume1.70 million shs
Average Volume1.64 million shs
Market Capitalization$1.34 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.37
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections. It also offers licensed and owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinsons Disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The company has operations in the United States, Switzerland, India, Ireland, the United Kingdom and internationally. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.
Read More
Amneal Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.1Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 2.5 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.15 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone908-947-3120

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.63 billion
Cash Flow$1.25 per share
Book Value$1.16 per share

Profitability

Net Income$-361,920,000.00

Miscellaneous

Employees5,500
Market Cap$1.34 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$4.48
+0.20 (+4.67 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Amneal Pharmaceuticals (NYSE:AMRX) Frequently Asked Questions

How has Amneal Pharmaceuticals' stock been impacted by COVID-19?

Amneal Pharmaceuticals' stock was trading at $3.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AMRX stock has increased by 37.8% and is now trading at $4.48.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Amneal Pharmaceuticals?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last year. There are currently 2 sell ratings, 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Amneal Pharmaceuticals
.

When is Amneal Pharmaceuticals' next earnings date?

Amneal Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Amneal Pharmaceuticals
.

How were Amneal Pharmaceuticals' earnings last quarter?

Amneal Pharmaceuticals Inc (NYSE:AMRX) announced its earnings results on Thursday, August, 6th. The company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.10 by $0.03. The company earned $464.60 million during the quarter, compared to the consensus estimate of $454.26 million. Amneal Pharmaceuticals had a negative net margin of 11.16% and a positive return on equity of 30.64%. The company's revenue was up 14.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.09 earnings per share.
View Amneal Pharmaceuticals' earnings history
.

What guidance has Amneal Pharmaceuticals issued on next quarter's earnings?

Amneal Pharmaceuticals issued an update on its FY20 earnings guidance on Thursday, August, 6th. The company provided earnings per share (EPS) guidance of $0.45.0.60 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.56. The company issued revenue guidance of $1.875-1.975 billion, compared to the consensus revenue estimate of $1.91 billion.

What price target have analysts set for AMRX?

10 brokerages have issued 1 year price objectives for Amneal Pharmaceuticals' stock. Their forecasts range from $3.00 to $7.00. On average, they expect Amneal Pharmaceuticals' share price to reach $4.86 in the next year. This suggests a possible upside of 8.4% from the stock's current price.
View analysts' price targets for Amneal Pharmaceuticals
.

Are investors shorting Amneal Pharmaceuticals?

Amneal Pharmaceuticals saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 7,390,000 shares, an increase of 26.8% from the June 15th total of 5,830,000 shares. Based on an average daily volume of 1,730,000 shares, the days-to-cover ratio is presently 4.3 days. Approximately 7.8% of the shares of the company are short sold.
View Amneal Pharmaceuticals' Short Interest
.

Who are some of Amneal Pharmaceuticals' key competitors?

What other stocks do shareholders of Amneal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amneal Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Teva Pharmaceutical Industries (TEVA), Micron Technology (MU), Cisco Systems (CSCO), General Electric (GE), Bausch Health Companies (BHC), NIO (NIO), NVIDIA (NVDA), Opko Health (OPK) and TherapeuticsMD (TXMD).

Who are Amneal Pharmaceuticals' key executives?

Amneal Pharmaceuticals' management team includes the following people:
  • Mr. Paul M. Bisaro, Exec. Chairman (Age 58)
  • Mr. Chirag K. Patel, Co-Founder & Co-Chairman (Age 52)
  • Mr. Chintu Patel, Co-Founder & Co-Chairman (Age 47)
  • Mr. Robert A. Stewart, Pres, CEO & Director (Age 51)
  • Ms. Nikita Shah, Sr. VP & Chief HR Officer (Age 41)

What is Amneal Pharmaceuticals' stock symbol?

Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX."

Who are Amneal Pharmaceuticals' major shareholders?

Amneal Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.75%), Neuberger Berman Group LLC (1.25%), Prudential Financial Inc. (0.40%), Bank of New York Mellon Corp (0.35%), LSV Asset Management (0.31%) and Charles Schwab Investment Management Inc. (0.25%). Company insiders that own Amneal Pharmaceuticals stock include Andrew S Boyer, Chintu Patel, Chirag K Patel, Gautam Patel, International Ltd Fosun, Jeffrey P George, John Kiely, Joseph Todisco, Paul Bisaro, Paul M Meister, Peter R Terreri, Pradeep Bhadauria and Ted C Nark.
View institutional ownership trends for Amneal Pharmaceuticals
.

Which institutional investors are selling Amneal Pharmaceuticals stock?

AMRX stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Goldman Sachs Group Inc., Bank of New York Mellon Corp, Jacobs Levy Equity Management Inc., Spark Investment Management LLC, Neuberger Berman Group LLC, Bank of America Corp DE, and Two Sigma Advisers LP.
View insider buying and selling activity for Amneal Pharmaceuticals
.

Which institutional investors are buying Amneal Pharmaceuticals stock?

AMRX stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., LSV Asset Management, Vanguard Group Inc., Bridgeway Capital Management Inc., Prudential Financial Inc., Smith Asset Management Group LP, Cubist Systematic Strategies LLC, and Engineers Gate Manager LP. Company insiders that have bought Amneal Pharmaceuticals stock in the last two years include Andrew S Boyer, Chintu Patel, Chirag K Patel, Gautam Patel, International Ltd Fosun, Jeffrey P George, John Kiely, Joseph Todisco, Paul Bisaro, Paul M Meister, Pradeep Bhadauria, and Ted C Nark.
View insider buying and selling activity for Amneal Pharmaceuticals
.

How do I buy shares of Amneal Pharmaceuticals?

Shares of AMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amneal Pharmaceuticals' stock price today?

One share of AMRX stock can currently be purchased for approximately $4.48.

How big of a company is Amneal Pharmaceuticals?

Amneal Pharmaceuticals has a market capitalization of $1.34 billion and generates $1.63 billion in revenue each year. The company earns $-361,920,000.00 in net income (profit) each year or $0.27 on an earnings per share basis. Amneal Pharmaceuticals employs 5,500 workers across the globe.

What is Amneal Pharmaceuticals' official website?

The official website for Amneal Pharmaceuticals is www.amneal.com.

How can I contact Amneal Pharmaceuticals?

Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company can be reached via phone at 908-947-3120 or via email at [email protected]

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.